1618 GMT - News that the U.S. Food and Drug Administration declared the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic over marks an important step toward a normalized obesity-drug market in the U.S., Barclays analysts say in a note. The move should eventually lead to pharmacies or physicians no longer producing copies of the branded drugs, Barclays says. Nevertheless, the exact date when copycat versions of the drugs come off market remains somewhat uncertain, the analysts say. The FDA designation shows the Danish pharmaceutical company's efforts to scale up production have reached a level that it can now supply the market for type 2 diabetes and obesity, Barclays says. Shares rise 5.8%. (adria.calatayud@wsj.com)
(END) Dow Jones Newswires
February 21, 2025 11:18 ET (16:18 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。